Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$2.88 USD
+0.08 (2.86%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Balance Sheet
Fiscal Year End for Xeris Biopharma Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 72 | 122 | 102 | 134 | 76 |
Receivables | 39 | 31 | 17 | 7 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 39 | 25 | 18 | 8 | 2 |
Other Current Assets | 6 | 9 | 5 | 3 | 4 |
Total Current Assets | 156 | 187 | 143 | 152 | 87 |
Net Property & Equipment | 6 | 6 | 7 | 7 | 8 |
Investments & Advances | 0 | 0 | 0 | 0 | 13 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 133 | 143 | 154 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 1 | 0 | 0 |
Total Assets | 323 | 345 | 304 | 159 | 109 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 12 | 5 | 9 | 3 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 60 | 65 | 68 | 25 | 21 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 20 | 3 | 2 | 0 | 0 |
Total Current Liabilities | 95 | 74 | 79 | 28 | 27 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 4 | 12 | 7 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 191 | 187 | 88 | 87 | 58 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 26 | 30 | 4 | 9 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 329 | 299 | 209 | 125 | 95 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 610 | 600 | 555 | 371 | 261 |
Retained Earnings | -617 | -555 | -460 | -337 | -246 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -7 | 45 | 95 | 34 | 14 |
Total Liabilities & Shareholder's Equity | 323 | 345 | 304 | 159 | 109 |
Total Common Equity | -7 | 45 | 95 | 34 | 14 |
Shares Outstanding | 138.10 | 135.50 | 66.50 | 48.90 | 27.00 |
Book Value Per Share | -0.05 | 0.33 | 1.43 | 0.69 | 0.53 |
Fiscal Year End for Xeris Biopharma Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 78 | 87 | 72 | 66 | 81 |
Receivables | 42 | 37 | 39 | 46 | 30 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 43 | 41 | 39 | 38 | 37 |
Other Current Assets | 7 | 8 | 6 | 8 | 8 |
Total Current Assets | 170 | 173 | 156 | 158 | 156 |
Net Property & Equipment | 6 | 6 | 6 | 6 | 7 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 127 | 130 | 133 | 135 | 138 |
Deposits & Other Assets | 5 | 5 | 5 | 5 | 5 |
Total Assets | 332 | 337 | 323 | 328 | 329 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 7 | 12 | 12 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 17 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 63 | 60 | 60 | 54 | 48 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 20 | 19 | 2 |
Total Current Liabilities | 75 | 73 | 95 | 87 | 80 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 3 | 3 | 2 | 3 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 230 | 230 | 191 | 190 | 188 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8 | 6 | 9 | 10 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 351 | 346 | 329 | 324 | 315 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 632 | 627 | 610 | 608 | 605 |
Retained Earnings | -651 | -636 | -617 | -604 | -591 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -19 | -9 | -7 | 4 | 14 |
Total Liabilities & Shareholder's Equity | 332 | 337 | 323 | 328 | 329 |
Total Common Equity | -19 | -9 | -7 | 4 | 14 |
Shares Outstanding | 148.20 | 148.20 | 138.10 | 138.00 | 135.50 |
Book Value Per Share | -0.13 | -0.06 | -0.05 | 0.03 | 0.10 |